Pityriasis rosea, pityriasis rosea-like eruptions, and herpes zoster in the setting of COVID-19 and COVID-19 vaccination. [PDF]
Drago F, Broccolo F, Ciccarese G.
europepmc +1 more source
Reply to: Pityriasis rosea and pityriasis rosea–like eruptions
Papadavid, Evangelia +6 more
openaire +3 more sources
Imatinib mesylate-induced cutaneous rash masquerading as pityriasis rosea of Gilbert
Prashant Verma +2 more
openalex +1 more source
A retrospective analysis of medications associated with pityriasis rosea reported in the FDA adverse events reporting system. [PDF]
Mashoudy KD, Ye-Tay J, Nouri K.
europepmc +1 more source
Pityriasis rosea and pityriasis rosea-like eruption after anti-SARS-CoV-2 vaccination: a report of five cases and review of the literature. [PDF]
Veraldi S +3 more
europepmc +1 more source
Pityriasis rosea and pityriasis rosea-like eruption: The distinction is relevant for diagnostic and prognostic reasons. [PDF]
Ciccarese G, Serviddio G, Drago F.
europepmc +1 more source
Pityriasis Rosea and Immunosuppressive Drugs [Response to Letter]. [PDF]
Wu H, Ji QJ, Xu YY, Zhu JW.
europepmc +1 more source
Reply to "the significance of investigating clinical, histopathologic and virological features in pityriasis rosea and pityriasis rosea-like eruptions following COVID-19 vaccinations" by Ciccarese G. et al. [PDF]
Martora F +4 more
europepmc +1 more source
Pityriasis Rosea Following Covaxin (BBV152) Vaccination for COVID-19. [PDF]
Singh BSTP, Kar BR, Agrawal I.
europepmc +1 more source
Atypical Pityriasis rosea in a black child: a case report [PDF]
A Amer +12 more
core +2 more sources

